Note 11 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | 87 Months Ended | |||
|---|---|---|---|---|---|---|
May 31, 2022 |
Sep. 18, 2015 |
Sep. 30, 2015 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2022 |
|
| Proceeds From Sale of Royalty and Milestone Rights | $ 65,000 | $ 65,000 | ||||
| Consideration Paid for Termination of Royalty Monetization | $ 100 | $ 100 | $ 100 | |||
| Non-cash Gain on Termination of Liability Related to Sale of Future Royalties | $ 84,100 | $ 84,152 | $ (0) | |||
| Effective Annual Interest Rate | 3.20% | 3.50% | ||||
| SWK [Member] | ||||||
| Percentage of Royalties and Rights Under Agreement | 75.00% | |||||
| SWK [Member] | First Four Commercial Milestones [Member] | ||||||
| Percentage of Royalties and Rights Under Agreement | 80.00% | |||||
| Commercial Milestones Value Maximum Amount Available | $ 35,600 | |||||
| AcelRX [Member] | First Four Commercial Milestones [Member] | ||||||
| Commercial Milestones Value Maximum Amount Available | $ 44,500 | |||||